# EMV Capital advances XF-73 toward late-stage trials for surgical infection prevention

Page: https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention
Text version: https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention.md
Podcast: [Proactive - Interviews for investors](https://stenobird.com/podcast/proactive-interviews-for-investors-1457173)
Published: 2026-05-28T14:23:26+00:00
Episode link: https://proactive-interviews-for-investors.simplecast.com/episodes/20260527-emv-capitalmp3-cHJmKFwr
Audio file: https://cdn.simplecast.com/media/audio/transcoded/1068c7db-2e26-4675-9674-33cc0c49ccdc/b96906c8-b386-47e4-a142-589b24379f8e/episodes/audio/group/d9cc03b1-022d-4a42-9f0f-4564ce83f695/group-item/2676051c-34f9-4363-97cb-206e2f3358d5/128_default_tc.mp3?aid=rss_feed&feed=xjpdm5C9
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/proactive-interviews-for-investors-1457173/episodes/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention
Duration seconds: 619

## Resource

EMV Capital CEO Dr. Ilian Iliev and Executive Chairman Nigel Brooksby joined Steve Darling from Proactive to discuss the company’s progress in advancing XF-73, an antimicrobial drug candidate designed to help prevent surgical site infections. The program represents an important step in addressing a significant healthcare challenge, particularly as hospitals and healthcare systems continue searching for more effective approaches to reduce infection risks and improve patient outcomes. XF-73 is being developed as a first-in-class topical antimicrobial treatment intended to rapidly eliminate harmful bacteria before surgery. The therapy targets bacteria commonly found in the nasal cavity that can contribute to post-surgical infections and complications. Management highlighted that a previous Phase 2 clinical study demonstrated a 99.5% reduction in bacterial nasal carriage within just 24 hours among surgical patients, providing encouraging support for the treatment’s potential effectiveness. The company acquired XF-73 and related intellectual property from Destiny Pharma in September 2025 through its Morai Acquisitions vehicle, which was subsequently renamed AMR Bio. Following the transaction, EMV Capital completed a funding round of approximately £1.3 million aimed at supporting the establishment and continued development of the new business. Brooke explained that several important regulatory milestones are expected to drive progress for the program. Planned near-term activities include filing an Investigational New Drug application for XF-73 Nasal, preparing for a Phase 3 trial, qualifying Infectious Disease Product designation, and advancing discussions with the U.S. Food and Drug Administration. The company also announced that Cardinal Health has been appointed as AMR Bi…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/proactive-interviews-for-investors-1457173/episodes/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.